8-K filed Aug 4, 2026 at 07:00 ET
Bruker reported Q2 2026 revenue of $838.5M (+5.2% YoY, +2.8% organic), beating consensus of $853.6M on the top line. Non-GAAP EPS of $0.49 was well above the $0.38 consensus estimate, driven by strong margin expansion (non-GAAP operating margin 14.1% vs 9.0% a year ago) and 10% organic bookings growth in the Scientific Instruments segment. The company slightly lowered its FY2026 revenue guidance range to $3.54-$3.57B (from $3.57-$3.60B) due to currency and tax, but maintained its non-GAAP EPS guidance of $2.10-$2.15. A $134.9M non-cash goodwill impairment charge drove a GAAP loss of $(0.41) per share, but the underlying operational beat and margin story are the key takeaways for the common stock.